Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $93.25 in the prior trading day, Haemonetics Corp. (NYSE: HAE) closed at $92.60, down -0.70%. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 0.89 million shares were traded. HAE stock price reached its highest trading level at $94.99 during the session, while it also had its lowest trading level at $86.81.
Ratios:
Our goal is to gain a better understanding of HAE by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 36.85. For the most recent quarter (mrq), Quick Ratio is recorded 1.76 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on October 13, 2022, initiated with a Buy rating and assigned the stock a target price of $90.
Citigroup Downgraded its Buy to Neutral on December 15, 2021, whereas the target price for the stock was revised from $75 to $59.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 06 ’24 when Lingamneni Anila sold 2,305 shares for $95.00 per share. The transaction valued at 218,975 led to the insider holds 12,295 shares of the business.
Strong Stewart W sold 228 shares of HAE for $20,668 on Sep 12 ’23. The President, Global Hospital now owns 16,221 shares after completing the transaction at $90.65 per share. On Sep 11 ’23, another insider, Lingamneni Anila, who serves as the EVP, Chief Technology Officer of the company, sold 2,305 shares for $90.00 each. As a result, the insider received 207,450 and left with 14,495 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 4735804928 and an Enterprise Value of 5411738624. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.57, and their Forward P/E ratio for the next fiscal year is 17.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.70 while its Price-to-Book (P/B) ratio in mrq is 4.99. Its current Enterprise Value per Revenue stands at 4.261 whereas that against EBITDA is 18.464.
Stock Price History:
Over the past 52 weeks, HAE has reached a high of $97.12, while it has fallen to a 52-week low of $70.74. The 50-Day Moving Average of the stock is 11.07%, while the 200-Day Moving Average is calculated to be 8.93%.
Shares Statistics:
The stock has traded on average 479.85K shares per day over the past 3-months and 537920 shares per day over the last 10 days, according to various share statistics. A total of 50.45M shares are outstanding, with a floating share count of 50.29M. Insiders hold about 0.98% of the company’s shares, while institutions hold 100.88% stake in the company. Shares short for HAE as of 1713139200 were 2238336 with a Short Ratio of 4.66, compared to 1710460800 on 2178251. Therefore, it implies a Short% of Shares Outstanding of 2238336 and a Short% of Float of 6.710000000000001.
